Alzheimer's Disease (AD) is a debilitating neurodegenerative disease that is characterized by cognitive decline.
It is the most common form of dementia,accounting for over 60% of cases and affecting over 33 million people worldwide.
Unfortunately the current approved AD treatments only provide limited therapeutic benefits.
Unfortunately the current approved AD treatments only provide limited therapeutic benefits.
There are four approved drugs available, but unfortunately, all of them have been associated with adverse effects. Acetylcholinesterase inhibitors may cause nausea, vomiting, diarrhea and weight loss, while memantine is known to cause hallucinations, dizziness and fatigue.Furthermore, none of these treatments prevent or reverse the progression of the disease but rather they treat the disease symptoms with limited efficacy
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties. It is investigated as a potential multifunctional treatment option for AD.
Here, we summarize the current status quo of effects of CBD in established pharmacological and transgenic animal models for AD.The phytocannabinoid cannabidiol (CBD) is a prime candidate for this new treatment strategy.
The in vivo therapeutic potential of CBD in AD has not been widely documented, however, there are a number of studies that have reported the effect of CBD in pharmacological models of AD. These studies have described anti-inflammatory and neuroprotective effects of CBD.